Cyberknife Radiosurgery for Locally Advanced Pancreatic Cancer

Not Recruiting

Trial ID: NCT00233415


The purpose of the trial is to test the efficacy of combining conventional chemoradiotherapy with radiosurgery for locally advanced pancreas cancer.

Official Title

Phase II Study to Evaluate the Efficacy of Conventional Chemoradiotherapy Followed by Stereotactic Radiosurgery for Locally Advanced Pancreatic Cancer

Stanford Investigator(s)

Quynh-Thu Le, MD
Quynh-Thu Le, MD

Katharine Dexter McCormick and Stanley McCormick Memorial Professor and Professor, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS)

Iris C. Gibbs, MD, FACR, FASTRO
Iris C. Gibbs, MD, FACR, FASTRO

Professor of Radiation Oncology (Radiation Therapy) and, by courtesy, of Neurosurgery

George A. Fisher Jr.
George A. Fisher Jr.

Colleen Haas Chair in the School of Medicine


Inclusion Criteria:- Pancreatic tumors not to exceed 7.5 cm.

   - Histologically confirmed malignancies of the pancreas, (ampulla of Vater or
   periampullary duodenum, tumors may be included when the head of pancreas is
   secondarily involved and unresectable criteria are met).

   - Unresectable by CT criteria or unresectable at exploratory laparotomy or laparoscopy.
   CT criteria for unresectability include encasement of the superior mesenteric vein
   (SMV), portal vein (PV) or invasion of the celiac artery or superior mesenteric artery

   - Patients with metastatic disease may be treated if they are symptomatic from the
   primary tumor.

   - Eastern Clinical Oncology Group performance status 0, 1 or 2. Exclusion
   Criteria:Chemotherapy within 1 month of registration.


device: Stereotactic Radiosurgery (Cyberknife)

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Stanford Cancer Clinical Trials Office

New Trial Alerts